Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
Department of Oncology, PLA General Hospital, Beijing, 100037, China.
Hum Genomics. 2021 Apr 12;15(1):21. doi: 10.1186/s40246-021-00320-9.
Non-small cell lung carcinoma (NSCLC) is one of the most common human cancers, comprising approximately 80-85% of all lung carcinomas. An estimated incidence of NSCLC is approximately 2 million new cases per year worldwide.
In recent decade, the treatment of NSCLC has made breakthrough progress owing to a large number of targeted therapies which were approved for clinical use. Epidemiology, genetic susceptibility, and molecular profiles in patients are likely to play an important factor in response rates and survival benefits to these targeted treatments and thus warrant further investigation on ethnic differences in NSCLC. In this study, a total number of 1500 Chinese patient samples,1000 formalin fixed paraffin-embedded (FFPE) and 500 blood samples, from patients with NSCLC were analyzed by targeted sequencing to explore mutational landscape in ethnic groups associated with China.
Overall, the data presented here provide a comprehensive analysis of NSCLC mutational landscape in Chinese patients and findings are discussed in the context of similar studies on different ethnic groups.
非小细胞肺癌(NSCLC)是最常见的人类癌症之一,约占所有肺癌的 80-85%。全球每年估计有 200 万例新的 NSCLC 病例。
由于大量已批准用于临床的靶向治疗药物,最近十年 NSCLC 的治疗取得了突破性进展。患者的流行病学、遗传易感性和分子特征可能是这些靶向治疗反应率和生存获益的重要因素,因此需要进一步研究 NSCLC 中的种族差异。在这项研究中,通过靶向测序分析了来自 NSCLC 患者的 1500 例中国患者样本(1000 例福尔马林固定石蜡包埋(FFPE)和 500 例血液样本),以探索与中国相关的人群中的突变景观。
总体而言,这里提供的 NSCLC 在中国患者中的突变景观的综合分析数据,并结合不同种族的类似研究进行了讨论。